Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Todd A DaviesRaul Goldschmidt

Abstract

Seven-valent pneumococcal conjugate vaccine (PCV7) provides protection against invasive pneumococcal disease that extends to unvaccinated populations, such as elderly or immunocompromised adults. PCV7 also reduces incidence of pneumococcal penicillin resistance. In this study, the potential impact of PCV7 on pneumococcal fluoroquinolone resistance was examined. U.S. levofloxacin-resistant isolates (264) from TRUST surveillance studies (1999-2004) were serotyped and quinolone resistance-determining region of parC/E and gyrA/B sequenced. Changes in prevalence of vaccine/nonvaccine serotypes during 2000-2004 and 1999-2004 were analyzed by regression analyses and chi-square trend test. The introduction of PCV7 (2000-2004) did not affect fluoroquinolone resistance prevalence, but mutants with vaccine serotypes declined linearly at -6.6 +/- 0.8% per year (p = 0.003), with concomitant replacement by nonvaccine serotypes; vaccine-related serotypes (6A, 9N, 19A, and 23N) increased (p = 0.04). Differential selection between vaccine and nonvaccine serotypes occurred for mutants containing amino acid substitutions at either ParC Ser79 (p = 0.01) or both ParC Ser79 and GyrA Ser81 (p = 0.04). Among mutants with ParC Ser79 substitutions, vacc...Continue Reading

References

Oct 1, 1992·Antimicrobial Agents and Chemotherapy·L K McDougalF C Tenover
Aug 1, 1991·The Journal of Infectious Diseases·R MuñozB G Spratt
Oct 1, 1996·Antimicrobial Agents and Chemotherapy·X S PanL M Fisher
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W P HausdorffG R Siber
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G BartlettM J Fine
Apr 13, 2001·JAMA : the Journal of the American Medical Association·K A RobinsonUNKNOWN Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·M S NiedermanUNKNOWN American Thoracic Society
Aug 2, 2003·Emerging Infectious Diseases·Mina Ebrahimi-RadBrigitte Gicquel
Mar 5, 2004·The Lancet Infectious Diseases·D BogaertP W M Hermans
Aug 12, 2004·JAMA : the Journal of the American Medical Association·Gili Regev-YochayEthan Rubinstein
Feb 1, 2005·The Lancet Infectious Diseases·William P HausdorffKeith P Klugman
Jun 21, 2005·Emerging Infectious Diseases·Crystal N JohnsonKen B Waites
Oct 27, 2005·JAMA : the Journal of the American Medical Association·Catherine A LexauUNKNOWN Active Bacterial Core Surveillance Team
Nov 4, 2005·The Journal of Infectious Diseases·Rekha PaiUNKNOWN Active Bacterial Core Surveillance Team
Apr 7, 2006·The New England Journal of Medicine·Moe H KyawUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Nov 23, 2006·Antimicrobial Agents and Chemotherapy·Daniel E RozenKeith P Klugman

❮ Previous
Next ❯

Citations

Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jennifer B RosenUNKNOWN CDC Emerging Infections Program Network
Feb 17, 2009·The Journal of Antimicrobial Chemotherapy·P L HoK H Chow
Feb 24, 2010·Antimicrobial Agents and Chemotherapy·Brian J MorrowKaren Bush
Feb 15, 2012·Vaccine·Jae-Hoon SongBernard Fritzell
Mar 4, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J MatthijnssensUNKNOWN RotaBel study group
Jun 14, 2018·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Yu-Hua Ma, Gui-Sheng Ye
Feb 19, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ravinder KaurMichael E Pichichero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.